- Home
- KNRX vs LNAI Comparison
KNRX vs LNAI Comparison
Compare KNRX & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | LNAI |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 29 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 12.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KNRX | LNAI |
|---|---|---|
| Price | $0.42 | $2.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 106.2K | ★ 696.2K |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.15 |
| 52 Week High | $3.45 | $5.02 |
Technical Indicators
Market Signals| Indicator | KNRX | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 49.53 |
| Support Level | $0.39 | $0.89 |
| Resistance Level | $0.50 | $3.38 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 37.35 | 8.11 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.